abcam

ab46679

Anti-CD16 antibody [MEM-154] - BSA and Azide free

Key facts

Isotype	IgG1
Host species	Mouse
Storage buffer	pH: 7.4 Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	Cell preparation containing FCGR3A protein. The exact immunogen used to generate this antibody is proprietary information. Database link P08637
Carrier free	Yes
Clone number	MEM-154
Purification technique	Affinity purification Protein A
Specificity	The antibody MEM-154 reacts with the epitope on CD16 antigen residing in proximity to FG loop (probably BC or C'E loop). CD16 is a low affinity receptor for aggregated IgG (FcγRIII antigen). MEM-154 recognizes a polymorphism of CD16a (NK cells form), it reacts well with granulocyte form (CD16b) of all subjects. The antibody blocks binding of human IgG to FcγRIII.
Concentration	1 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →
Purification notes	Purified from hybridoma culture supernatant. Purity >95% by SDS-PAGE.

Reactivity data

Flow Cyt

Tested

Species	Human
Dilution info	1 µg for 10^6 Cells
Notes	ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

Target data

See full target information FCGR3A

Function

Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger (PubMed:11711607, PubMed:21768335, PubMed:22023369, PubMed:24412922, PubMed:25786175, PubMed:25816339, PubMed:28652325, PubMed:8609432, PubMed:9242542). Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC (PubMed:24412922, PubMed:25786175). Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis (PubMed:29967280, PubMed:9916693). Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation (PubMed:1825220, PubMed:23024279, PubMed:2532305). Costimulates NK cells and trigger lysis of target cells independently of IgG binding (PubMed:10318937, PubMed:23006327). Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells (PubMed:27670158). Mediates enhanced opsonisation and ADCC in response to afucosylated IgGs (PubMed:34485821, PubMed:28566370). (Microbial infection) Involved in Dengue virus pathogenesis via antibody-dependent enhancement (ADE) mechanism. Secondary infection with Dengue virus triggers elevated levels of afucosylated non-neutralizing IgG1s with reactivity to viral envelope/E protein. Viral antigen-IgG1 complexes bind with high affinity to FCGR3A, facilitating virus entry in myeloid cells and subsequent viral replication.

Storage

Shipped at conditions	Blue Ice

Appropriate short-term storage duration	1-2 weeks
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	-20°C
Aliquoting information	Upon delivery aliquot

Notes

Preserved by filter sterilization.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	CD16 also known as FCGR3A or CD16A protein is a low-affinity receptor for the Fc region of IgG. It weighs approximately 50-70 kDa and exists on the surface of several immune cells such as natural killer (NK) cells some populations of T cells and macrophages. The expression of CD16 mediates various cellular responses including antibody-dependent cellular cytotoxicity (ADCC) where it acts by engaging with immune complexes. Researchers often use anti-CD16 antibodies in flow cytometry to analyze the presence and quantity of CD16-expressing cells.
Biological function summary	This receptor plays a significant role in immune system regulation by contributing to the activation of immune effector cells. CD16 is not part of a larger complex but it operates in concert with CD3 proteins to trigger intracellular signaling pathways upon engagement with its ligand. Its function is important for the antibody-dependent clearance of infected or malignant cells from the body representing an essential linkage between innate and adaptive immunity.
Pathways	Signaling involving CD16 is integrated into the immune response mechanisms that include the Fc gamma receptor-mediated phagocytosis pathway. This pathway involves interactions with IgG antibodies and complements the activity of other Fc gamma receptors such as CD32 and CD64. Through these interactions CD16 enhances phagocytic activity and stimulates the secretion of cytokines and chemokines important for orchestrating an effective immune response.
Associated diseases and disorders	CD16 plays an important role in conditions like autoimmune diseases and certain cancers. Its expression and function are important in the pathophysiology of systemic lupus erythematosus where an imbalance in immune complex clearance leads to tissue damage. In oncology CD16 aids in the immune system's recognition and elimination of tumor cells working alongside proteins such as CD3 in modulating the body's anti-tumor response. Understanding CD16's involvement in these diseases helps in developing therapeutic strategies that harness the immune system's power such as monoclonal antibody therapies targeting CD16.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.


3 product images



Flow Cytometry - Anti-CD16 antibody [MEM-154] - BSA and Azide free (ab46679)

CD16 Flow Cytometry staining using mouse Anti-CD16 antibody

Separation of human neutrophil granulocytes (red-filled) from CD16 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using ab46679 at 2 µg/ml.




Flow Cytometry - Anti-CD16 antibody [MEM-154] - BSA and Azide free (ab46679)

CD16 Flow Cytometry staining using mouse Anti-CD16 antibody

Human peripheral blood granulocytes stained with ab46679 (red line). Human whole blood was processed using a modified protocol based on Chow *et al*, 2005 (PMID: 16080188). In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 min at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 min at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 min at 4°C. Cells were then incubated with the antibody (ab46679, 1µg/1x10^6 cells) for 30 min at 4°C. The secondary antibody

used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 4°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1µg/1x10^6 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Gating strategy - peripheral blood granulocytes.



Flow Cytometry - Anti-CD16 antibody [MEM-154] - BSA and Azide free (ab46679)

CD16 Flow Cytometry staining using mouse Anti-CD16 antibody

Flow cytometry surface staining pattern of human peripheral blood stained using ab46679 at 2 µg/ml GAM APC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.